Researchers at IISc find Pranlukast has potential applications for TB therapy
Posted on June 4, 2024 Updated on June 2, 2024
![]() Pranlukast is a drug typically used to treat asthma and allergic rhinitis by inhibiting leukotrienes which are chemicals released by the human body. This approach seems promising because it utilizes the body’s own immune system to combat the infection and promote tissue repair. Further studies and clinical trials will be necessary to fully understand the efficacy and safety of using pranlukast in this context, but the initial findings suggest a promising avenue for improving tuberculosis treatment, said the report. PRK belongs to a class of drugs that hinder the action of leukotriene which are inflammatory molecules by binding to the receptor with antagonistic action without an antagonistic effect. The researchers contend that induction of PRK would in turn help improve the efficacy and shorten the duration of the currently used TB treatment. The idea of recruiting pro-healing immune regulatory macrophages suggests a targeted approach to combating TB. Macrophages play a crucial role in the immune response, and harnessing their pro-healing properties could aid in repairing the damage caused by TB infection, said the report. |
This entry was posted in Clinical Trial.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://auroushealthcare.wordpress.com/2024/06/04/researchers-at-iisc-find-pranlukast-has-potential-applications-for-tb-therapy/